This guideline only refers to treatment of adult patients with heterozygous familial hypercholesterolaemia (HeFH) and
- LDL-C ≥5.0mmol/L, for primary prevention of cardiovascular events.
- LDL-C ≥3.5mmol/L, for secondary prevention of cardiovascular events.
Treatment will be managed by specialists within NHS GGC lipid clinics
- All patients with suspected HeFH should be referred to a Lipid Clinic for confirmation of the diagnosis, assessment and management.
- All known HeFH patients with uncontrolled hyperlipidaemia despite maximum treatment with a statin ± ezetimibe should be referred to a Lipid Clinic for consideration of a PCSK9 inhibitor.
N.B. Please refer to the Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guideline for the management of hypercholesterolaemia in high-risk cardiovascular disease patients without FH.